SCHEMBL2415488

SCHEMBL2415488

CS(=O)(=O)c1nccc(-c2ccc(OC(F)(F)F)cc2)n1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.49
ALDH1A1 P00352 3/20 0.49
NPSR1 Q6W5P4 3/20 0.49
TP53 P04637 3/20 0.49
SMN1; SMN2 Q16637 2/20 0.49
HPGD P15428 2/20 0.49
KMT2A Q03164 2/20 0.49
USP2 O75604 1/20 0.49
KIF11 P52732 1/20 0.47
SCN5A Q14524 3/20 0.45
ABL1 P00519 3/20 0.45
BCR P11274 3/20 0.45
RAB9A P51151 3/20 0.43
PTGS2 P35354 2/20 0.43
NPC1 O15118 1/20 0.43
GAA P10253 1/20 0.43
MAPT P10636 1/20 0.43
SDHB P21912 2/20 0.43
LMNA P02545 2/20 0.43
STAT3 P40763 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18963 0.81 NPSR1 (0.49) KDM4EALDH1A1NPSR1TP53SMN1; SMN2
SCHEMBL3135636 0.81 SCN9A (0.54) KDM4EALDH1A1NPSR1TP53SMN1; SMN2
SCHEMBL2410945 0.79 RAB9A (0.56) KDM4EALDH1A1NPSR1TP53SMN1; SMN2
SCHEMBL22738476 0.78 SCN5A (0.50) KDM4EALDH1A1SCN5ARAB9ANPC1
SCHEMBL4071288 0.76 KMO (0.51) SMN1; SMN2KMT2APTGS2GAAMAPT
SCHEMBL24725108 0.76 SMN1; SMN2 (0.41) KDM4EALDH1A1NPSR1TP53SMN1; SMN2
SCHEMBL16538788 0.76 KCNH2 (0.53) KDM4EALDH1A1NPSR1TP53SMN1; SMN2
SCHEMBL28146826 0.76 NPC1 (0.45) KDM4EALDH1A1NPSR1TP53SMN1; SMN2
SCHEMBL4447801 0.76 BPTF (0.54) KDM4EALDH1A1NPSR1TP53SMN1; SMN2
SCHEMBL14637424 0.75 SCN5A (0.50) KDM4EALDH1A1SMN1; SMN2SCN5ARAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8026370-B2 Peroxisome proliferator antagonist; hyperlipemia agents; arteriosclerosis; antiischemic agents MITSUBISHI TANABE PHARMA CORPORATION (JP) 2011-09-27 US disclosed
US-20080167307-A1 Carboxylic Acid Derivative Containing Thiazole Ring and Pharmaceutical Use Thereof MITSUBISHI PHAMA CORPORATION (JP) 2008-07-10 US disclosed
EP-1816128-A1 CARBOXYLIC ACID DERIVATIVE CONTAINING THIAZOLE RING AND PHARMACEUTICAL USE THEREOF Mitsubishi Pharma Corporation (JP) 2007-08-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080167307-A1 Carboxylic Acid Derivative Containing Thiazole Ring and Pharmaceutical Use Thereof PPARA, PPARD, PPARG KDM4E 3335/4885ALDH1A1 175/4885NPSR1 1688/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.